Article
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
BMC cancer - 13 Apr 2010
Sánchez-Muñoz Alfonso, Gallego Elena, de Luque Vanessa, Pérez-Rivas Luís G, Vicioso Luís, Ribelles Nuria, Lozano José, Alba Emilio
Abstract excerpt
BACKGROUND: Mutational analysis of the KRAS gene has recently been established as a complementary in vitro diagnostic tool for the identification of patients with colorectal cancer who will not benefit from anti-epidermal growth factor receptor (EGFR) therapies. Assessment of the mutation status of KRAS might also be of potential relevance in other EGFR-overexpressing tumors, such as those occurring in breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.